Scientific exchange · Dr. Zoë Bauer

22 Aug 2026 · In person · Dr. Zoë Bauer, McGill University Health Centre · MSL Luis Ortega · Lumeva

ReviewedManualENG-0187—

Capture insight from this engagement

Location: McGill University Health Centre
Therapeutic area: Neurology
Country: Canada
Stakeholder tier: Tier 2
Strategic objective: Not linked
Initiative: Not linked
MSL: LOLuis OrtegaMSL, Neurology (Iberia)
Product: Lumeva (lumevarin)

Topics discussed

Dosing in hepatic impairment
Drug interactions
Medication-overuse headache

Scientific content used

Chronic migraine scientific platform

Questions raised

What is the persistence rate at 18 months in real-world cohorts?

Notes

Scientific exchange with primary care physician at McGill University Health Centre. Discussed dosing in hepatic impairment, drug interactions, medication-overuse headache.

Insights captured (1)

Capture insight

INS-0005High
Dosing in hepatic impairment
Dosing in hepatic impairment: request for data reported by primary care physician (CA).
Action created

Review workflow

Draft
Submitted
3Reviewed

Review complete. Quality ratings and insights can now be used in aggregates.

Follow-ups

Share MI standard response

0 of 1 complete

Quality ratings

1–5, rated at review

Scientific relevance: 2
Strategic relevance: 3
Depth of exchange: 4
Actionability: 3

Data lineage

Source system: Manual
Sync: Entered manually in Hub
System of record: Hub
Record id: ENG-0187

Audit history (0)

All create, update and approval events for this record

No audit events in sample data